Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated:  6/1/2016
Ohio State University Hospital East
mi
from
Columbus, OH
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated: 6/1/2016
Ohio State University Hospital East
mi
from
Columbus, OH
Click here to add this to my saved trials
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated:  6/1/2016
Ohio State University
mi
from
Columbus, OH
Comprehensive Frailty Assessment
Comprehensive Frailty Assessment
Status: Enrolling
Updated: 6/1/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS
Status: Enrolling
Updated:  6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS
Status: Enrolling
Updated: 6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Bexarotene in Patients With Acute Myeloid Leukemia
A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Bexarotene in Patients With Acute Myeloid Leukemia
A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 6/7/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias
Status: Enrolling
Updated:  6/7/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias
Status: Enrolling
Updated: 6/7/2016
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
University of California, San Francisco Department of Pediatrics
mi
from
San Francisco, CA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
University of California, San Francisco Department of Pediatrics
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Stanford University
mi
from
Stanford, CA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Nemours
mi
from
Wilmington, DE
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Nemours
mi
from
Wilmington, DE
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Childrens National Medical Center
mi
from
Washington,
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Nemours
mi
from
Jacksonville, FL
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Nemours
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Florida All Children's Hospital
mi
from
St. Petersburg, FL
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Florida All Children's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Oregon Health and Science University
mi
from
Portland, OR
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Texas Children's Cancer Center/Baylor College of Medicine
mi
from
Houston, TX
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Texas Children's Cancer Center/Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
University of Colorado
mi
from
Aurora, CO
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Tulane University Medical Center
mi
from
New Orleans, LA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Tulane University Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Children's Hospital Boston
mi
from
Boston, MA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated:  6/9/2016
Hospital for Sick Children
mi
from
Toronto,
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH
Status: Enrolling
Updated: 6/9/2016
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Childrens National Medical Center
mi
from
Washington,
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Children's Healthcare of Atlanta at Egleston and Scottish Rite
mi
from
Atlanta, GA
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Children's Healthcare of Atlanta at Egleston and Scottish Rite
mi
from
Atlanta, GA
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
LSU Health Sciences Center
mi
from
Shreveport, LA
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
University of Michigan Medical Center, Mott Children's Hospital
mi
from
Ann Arbor, MI
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
University of Michigan Medical Center, Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Columbus Children's Hospital
mi
from
Columbus, OH
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Columbus Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Cook Children's Hospital
mi
from
Fort Worth, TX
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Cook Children's Hospital
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated:  6/13/2016
Texas Children's Hospital
mi
from
Houston, TX
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Status: Enrolling
Updated: 6/13/2016
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial
Status: Enrolling
Updated:  6/13/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial
Status: Enrolling
Updated: 6/13/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial
Status: Enrolling
Updated:  6/13/2016
University of Torino
mi
from
Torino,
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial
Status: Enrolling
Updated: 6/13/2016
University of Torino
mi
from
Torino,
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
Mayo Clinic
mi
from
Jacksonville, FL
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated:  6/14/2016
Rambam Medical Center
mi
from
Haifa,
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Status: Enrolling
Updated: 6/14/2016
Rambam Medical Center
mi
from
Haifa,
Click here to add this to my saved trials
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  6/14/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 6/14/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  6/14/2016
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 6/14/2016
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  6/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 6/14/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  6/14/2016
Duke Medical Center
mi
from
Durham, NC
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 6/14/2016
Duke Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  6/14/2016
Taussig Cancer Center- Cleveland Clinic
mi
from
Cleveland, OH
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 6/14/2016
Taussig Cancer Center- Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated:  6/14/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated: 6/14/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated:  6/14/2016
Johns Hopkins University
mi
from
Baltimore, MD
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated: 6/14/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated:  6/14/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
Status: Enrolling
Updated: 6/14/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials